3,0
7 janv. 2015
Employé (anonyme)
Employé (ancien)
Recommande
Approbation du PDG
Perspective commerciale
Avantages
Diversity in Oncology portfolio, very strong in oncology.
Inconvénients
Its strength in oncology is due to its subsidiary: Genentech. It has no historical experience in oncology. While Genentech is open, dynamic, and innovative; Roche is stiff and very conservative...it could not make drug development by itself.